SEC For				074					-									
FORM 4 UNITED STA				SIAI	TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERSHIP										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
								Ínvestment (of 1940							
1. Name and Address of Reporting Person [*] Gros David-Alexandre C					2. Issuer Name and Ticker or Trading Symbol <u>Eledon Pharmaceuticals, Inc.</u> [ELDN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)		(First) (Middle) N PHARMACEUTICALS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/13/2024								☑ Officer (give title below) Other (specify below) ☑ Chief Executive Officer				
19800 MACARTHUR BLVD STE. 250				4	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ne)					
(Street) IRVINE	С	A	92612									filed by One Reporting Person filed by More than One Reporting n						
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication													
					the the	affirmative o	defens	icate that a trar se conditions of	f Rule	e 10b5-1(c	c). See Instru	iction 10.		or written p	lan that	t is intended	to satisfy	
Date				2. Transacti	ction 2A. Deemed Execution Date,		3. 4. Securiti		of, or Beneficial ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amoun	5	Form	vnership : Direct r Indirect	7. Nature of Indirect Beneficial			
				(Month/Day/Yea			ar) 8) Code V	, .	Amount	(A) or (D)	r Price	Owned Fol Reported		wing (I) (Instr. 4)		Ownership (Instr. 4)		
			Table II - [uired, Dis s, options					Owned			I		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	te, 4. Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable a Expiration Date (Month/Day/Year)		le and	7. Title and of Securiti Underlying Derivative (Instr. 3 ar	d Amount ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Exp Dat	piration te	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (right to buy)	\$2.3	06/13/2024		А		517,454		(1)	05/	/01/2033	Common Stock	517,454	\$0	517,4	54	D		

Explanation of Responses:

1. This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 517,454 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 129,363 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 388,091 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027.

/s/ Paul Little, as attorney-in-	
fact for David Alexandre C.	06/14/2024
Gros, M.D.	
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.